Начало › Рак на гърдата › Мичиган › Detroit
Клинични проучвания за Рак на гърдата в Detroit, MI
33 проучвания за Рак на гърдата търсят участници в обекти в и около Detroit (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
The Vanguard Study: Testing a New Way to Screen for Cancer
Набиране на участнициЗдравите доброволци са добре дошли
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Набиране на участнициНаблюдателно проучванеЗдравите доброволци са добре дошли
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Набиране на участнициФаза 2
- Henry Ford Hospital, Detroit
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Набиране на участнициФаза 3
- Henry Ford Health ( Site 0002), Detroit
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Набиране на участнициФаза 3
- Research Site, Detroit
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Набиране на участници
- Karmanos Cancer Center - Wayne State University, Detroit
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Набиране на участнициФаза 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Набиране на участнициФаза 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Набиране на участнициФаза 3
- Henry Ford Hospital, Detroit
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Набиране на участнициФаза 1/2
- Karmanos Cancer Institute, Detroit
- Brigitte Harris Cancer Pavilion BHCP, Detroit
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Набиране на участнициФаза 3
- Karmanos Cancer Center, Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Набиране на участнициФаза 1
- Karmanos Cancer Institiute, Detroit
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Набиране на участнициФаза 1
- Henry Ford Cancer Institute, Detroit
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Набиране на участнициФаза 1/2
- Henry Ford Hospital, Detroit
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Набиране на участнициФаза 1/2
- Wayne State University - Barbara Ann Karmanos Cancer Institute, Detroit
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Набиране на участнициФаза 3
- Henry Ford Health System, Detroit
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Набиране на участнициФаза 3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
Набиране на участници
- Karmanos Cancer Institute, Detroit
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Набиране на участнициФаза 3
- Wayne State University/Karmanos Cancer Institute, Detroit
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Набиране на участнициФаза 2/3
- Henry Ford Cancer- Detroit (Brigitte Harris Cancer Pavilion), Detroit
E-Mindfulness Approaches for Living After Breast Cancer
Набиране на участнициФаза 3
- Henry Ford Hospital, Detroit
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Набиране на участнициФаза 1/2
- Karmanos Cancer Institute, Detroit
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
Набиране на участнициЗдравите доброволци са добре дошли
- Henry Ford Health, Detroit
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Набиране на участнициФаза 1/2
- Henry Ford Health Hospital, Detroit
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Набиране на участнициФаза 1/2
- Henry Ford Hospital, Detroit
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Набиране на участнициФаза 3
- Henry Ford Health System, Detroit
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Набиране на участнициФаза 3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Study of the TheraBionic P1 Device in Breast Cancer
Набиране на участници
- Karmanos Cancer Institute, Detroit
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- Henry Ford Health System, Detroit
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Набиране на участнициФаза 1/2
- Karmanos Cancer Institute, Detroit
F-Tryptophan PET/CT in Human Cancers
Набиране на участнициФаза 1
- Karmanos Cancer Institute, Detroit
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Набиране на участнициФаза 3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
Набиране на участници
- Karmanos Cancer Institute, Detroit
Проучвания за Рак на гърдата в други градове
- New York City, NY136 проучвания
- Houston, TX126 проучвания
- Boston, MA112 проучвания
- Nashville, TN81 проучвания
- Los Angeles, CA73 проучвания
- Edison, NJ68 проучвания
- St. Louis, MO64 проучвания
- Queens, NY64 проучвания
- Durham, NC64 проучвания
- Chicago, IL59 проучвания
- Philadelphia, PA56 проучвания
- Dallas, TX55 проучвания
Други проучвания в Detroit
- Рак на белия дроб с недребноклетъчен тип44 проучвания
- Рак (всички видове)29 проучвания
- Колоректален рак26 проучвания
- Рак на яйчниците26 проучвания
- Метастатичен рак24 проучвания
- Рак на простатата22 проучвания
- Ендометриален рак21 проучвания
- Рак на белия дроб20 проучвания
- Множествен миелом19 проучвания
- Рак на стомаха16 проучвания
- Плоскоклетъчен карцином на главата и шията15 проучвания
- Остра миелоидна левкемия14 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.